Locust Walk Insights
LOCUST WALK INSIGHTS
2021 Q3 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 Q3 Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life sciences deal...
iPSC Market Overview
In this report you can find an overview and analysis of the following across the iPSC market: Summary of iPS-derived cell therapy development landscape and key clinical trials IPO and private financing activity and performance Public market performance relative to...
Bought Not Sold
How do you start an M&A discussion? Locust Walk has conducted an extensive study of mergers and acquisitions in biopharma completed in the past three years and uncovered an interesting trend leaders need to understand: the majority of acquirers only became...
2021 Q2 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 Q2 Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life sciences deal...
Crossover Evolution: The Evolving Role of the Crossover Financing Round
The Covid-19 pandemic was the biggest biopharma news of 2020. It may be hard to remember now, but in March of last year, biotech indices had quickly nose-dived, along with the broader market, as the reality of the pandemic became apparent. The prevailing financial...
2021 Q1 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 Q1 Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life sciences deal...
Boston Business Journal: Life sciences firm Locust Walk’s plans for its $175M SPAC
Geoff Meyerson co-founded Locust Walk, a Boston-based life sciences consulting firm, on Sept. 15, 2008, the same day that Lehman Brothers filed for bankruptcy and Merrill Lynch sold itself to Bank of America. Meyerson said he “figured the world didn’t need another...
Locust Walk 2020 Year End Report
Each quarter our team at Locust Walk compiles key statistics and trends on strategic transactions and financings. Our 2020 Year End Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life science deal...
Doubling Down: The Power of Asset Diversification in a Time of Robust Access to Capital
Q3 Report: Global Trends in Biopharma Transactions
Each quarter our team at Locust Walk compiles key statistics and trends on strategic transactions and financings. Our Q3 2020 Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life science deal landscape. ...
Panel Recording! Knocking At The Door: Challenges Women Face With Biopharma Boards
BIO (Biotech Innovation Organization) collected a survey in January of 2020 to better understand the current demographics of biopharma companies. Responses to their questions on representation indicate that the number of women...
Biopharma’s COVID Capital Comeback – A Whitepaper
What a difference a few months can make – especially during a pandemic. Heading into 2020, biopharma looked like it would be typecast in its typical election year role: the big business scapegoat for everything that’s wrong in health care. There had been the usual big...
Deal Makers of Japan, Volume 2, Exclusive Interviews
We are pleased to present the second series of the Deal Makers of Japan – Exclusive Interviews with Japan’s best dealmakers. We released our inaugural edition in March 2020 and have received numerous comments from biotech/biopharma companies around the world. Since...
Live Panel: The Unexpected IPO Boom for Biopharma in Q2
Locust Walk is partnering with Applied Molecular Transport, Forma Therapeutics, and Goodwin for a live panel on Thursday, July 23rd from 1-2 pm EST entitled "The Unexpected IPO Boom for Biopharma in Q2." CLICK HERE TO REGISTER Q2 saw a boom in IPOs, while many...
Q2 2020 Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q2 2020 Report applies the latest data to analyze current activities in the life science deal landscape.